In 2015, there were 47 million people with dementia worldwide. 1 The overall number of people with dementia is projected to reach 132 million in 2050, 51% of whom will be from Asian countries. 1 Japan has the highest prevalence of dementia among the OECD countries, where 2% of inhabitants (5 million) are living with dementia.
There are significant unmet needs regarding the effectiveness of antidementia drug use in real-world settings. The recommendations in guidelines might impact on the prescribing practices of antidementia drugs. Therefore, this study aimed to examine the prevalence of antidementia drug use in Japan.
We used a nationwide claims database, the National Database There were 1 733 916 prevalent users of antidementia drugs (Table 1 ). The annual prevalence of antidementia drug use was 1.4% among all inhabitants and 5.1% among those aged ≥65 years, with a peak of 17.0% among those aged ≥85 years. Users aged ≥85 years consumed 46.8% of the total quantity of antidementia drugs prescribed. The DID showed that 13 in 100 inhabitants aged ≥85 years received a maintenance dose of an antidementia drug every day. Similar findings were observed in both sexes.
To our knowledge, this is the first study to establish the prevalence of antidementia drug use in Japan. The prevalence of antidementia drug use among inhabitants aged ≥85 years seems to be incredibly high, compared to that reported in a nationwide study in Germany which yielded an annual prevalence of 18% even among people with dementia aged ≥85 years. The main limitation of this study is that our database did not cover approximately 5% of inhabitants aged ≥65 years. Nevertheless, our study provides evidence on the minimum prevalence of antidementia drug use in Japan.
